Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back
Abstract Session

Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
General Topic: Clinical Science

14T178: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA (2545–2550)

Tuesday, November 14, 2023
4:00 PM – 5:30 PM PT
Location: Exhibit Hall A-B

On Demand In Person Livestreamed

    Presenting Author(s)

  • KB

    Katie Bechman, PhD, MSc, MBChB

    King's College London
    London, United Kingdom

    Disclosure information not submitted.

  • Atul Deodhar, MD

    Professor of Medicine, Division of Arthritis and Rheumatic Diseases, School of Medicine
    Oregon Health & Science University
    Portland, OR, United States

    Disclosure information not submitted.

  • WM

    Walter P. Maksymowych, MD

    University of Alberta
    Edmonton, AB, Canada

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); CARE Arthritis Ltd: Officer or Board Member (Ongoing); CARE Arthritis Ltd.: Officer or Board Member (Ongoing); Celgene: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Gilead: Consultant (Ongoing); Janssen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • Cecile PHILIPPOTEAUX, MD, PharmD, MSc

    University Hospital Center of Lille
    Lille, France

    Disclosure information not submitted.

  • MR

    Martin Rudwaleit, MD

    Klinikum Bielefeld Rosenhoehe, Bielefeld University
    Bielefeld, Germany

    Disclosure information not submitted.

  • CS

    Carla Goncalves Schahin Saad, MD, PhD

    Faculdade de Medicina da Universidade de Sao Paulo
    Sao Paulo, S�o Paulo, Brazil

    Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

  • 4:00 PM – 4:10 PM PT
    Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study

    Presenting Author: Atul Deodhar, MD – Oregon Health & Science University

  • 4:10 PM – 4:15 PM PT
    Q&A
  • 4:15 PM – 4:25 PM PT
    Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up

    Presenting Author: Carla Goncalves Schahin Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo

  • 4:25 PM – 4:30 PM PT
    Q&A
  • 4:30 PM – 4:40 PM PT
    Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study

    Presenting Author: Cecile PHILIPPOTEAUX, MD, PharmD, MSc – University Hospital Center of Lille

  • 4:40 PM – 4:45 PM PT
    Q&A
  • 4:45 PM – 4:55 PM PT
    Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials

    Presenting Author: Martin Rudwaleit, MD – Klinikum Bielefeld Rosenhoehe, Bielefeld University

  • 4:55 PM – 5:00 PM PT
    Q&A
  • 5:00 PM – 5:10 PM PT
    Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT

    Presenting Author: Walter P. Maksymowych, MD – University of Alberta

  • 5:10 PM – 5:15 PM PT
    Q&A
  • 5:15 PM – 5:25 PM PT
    The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis

    Presenting Author: Katie Bechman, PhD, MSc, MBChB – King's College London

  • 5:25 PM – 5:30 PM PT
    Q&A
Back to Top